Home › Glycogen Storage Disease Type II › California › Irvine
Glycogen Storage Disease Type II clinical trials in Irvine, CA
5 studies for Glycogen Storage Disease Type II are looking for participants at sites in and around Irvine (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
RecruitingPhase 1
- University of California-Irvine, Irvine
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
RecruitingPhase 1/2
- University of California, Irvine (UCI), Irvine
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
RecruitingPhase 2
- University of California - Irvine Medical Center, Irvine
Pompe Disease Registry Protocol
RecruitingObservational study
- University of California at Irvine- Site Number : 840036, Irvine
A Global Prospective Observational Registry of Patients With Pompe Disease
RecruitingObservational study
- University of California Irvine, Irvine
Glycogen Storage Disease Type II trials in other cities
- Durham, NC8 studies
- Arlington, VA5 studies
- St. Louis, MO5 studies
- Philadelphia, PA4 studies
- Pittsburgh, PA4 studies
- Atlanta, GA4 studies
- New York City, NY4 studies
- Cincinnati, OH3 studies
- Phoenix, AZ3 studies
- Indianapolis, IN3 studies
- Jacksonville, FL3 studies
Other studies in Irvine
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer23 studies
- Cancer (all types)17 studies
- Metastatic Cancer16 studies
- Lung Cancer15 studies
- Prostate Cancer14 studies
- Multiple Myeloma13 studies
- Ovarian Cancer12 studies
- Alzheimer's Disease11 studies
- Head and Neck Squamous Cell Carcinoma11 studies
- Bladder Cancer11 studies
- Pancreatic Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.